Abstract:BACKGROUND:Restoring the capacity of endothelial progenitor cells (EPCs) to promote angiogenesis is the major therapeutic strategy of diabetic peripheral artery disease. The aim of this study was to investigate the effects of GLP-1 (glucagon-like peptide 1; 32-36)-an end product of GLP-1-on angiogenesis of EPCs and T1DM (type 1 diabetes) mice, as well as its interaction with the classical GLP-1R (GLP-1 receptor) pathway and its effect on mitochondrial metabolism. METHODS:In in vivo experiments, we conducted streptozocin-induced type 1 diabetic mice as a murine model of unilateral hind limb ischemia to examine the therapeutic potential of GLP-1(32-36) on angiogenesis. We also generated Glp1r-/- mice to detect whether GLP-1R is required for angiogenic function of GLP-1(32-36). In in vitro experiments, EPCs isolated from the mouse bone marrow and human umbilical cord blood samples were used to detect GLP-1(32-36)-mediated angiogenic capability under high glucose treatment. RESULTS:We demonstrated that GLP-1(32-36) did not affect insulin secretion but could significantly rescue angiogenic function and blood perfusion in ischemic limb of streptozocin-induced T1DM mice, a function similar to its parental GLP-1. We also found that GLP-1(32-36) promotes angiogenesis in EPCs exposed to high glucose. Specifically, GLP-1(32-36) has a causal role in improving fragile mitochondrial function and metabolism via the GLP-1R-mediated pathway. We further demonstrated that GLP-1(32-36) rescued diabetic ischemic lower limbs by activating the GLP-1R-dependent eNOS (endothelial NO synthase)/cGMP/PKG (protein kinase G) pathway. CONCLUSIONS:Our study provides a novel mechanism with which GLP-1(32-36) acts in modulating metabolic reprogramming toward glycolytic flux in partnership with GLP-1R for improved angiogenesis in high glucose-exposed EPCs and T1DM murine models. We propose that GLP-1(32-36) could be used as a monotherapy or add-on therapy with existing treatments for peripheral artery disease. REGISTRATION:URL: www.ebi.ac.uk/metabolights/; Unique identifier: MTBLS9543.

GLP-1 programs the neurovascular landscape

Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation

Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice

The central GLP-1: implications for food and drug reward

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Regulation of energy metabolism through central GIPR signaling

Brain–immune networks: a role for GLP1 receptor

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

GLP-1, a powerful physiological incretin: an update.

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists

Neuroprotective properties of GLP-1: theoretical and practical applications

GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function

Control of insulin secretion by GLP-1

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity